ZIOPHARM Oncology, Inc. (ZIOP) Stock: A Good Pick In The Biotechnology Sector?

0
121

ZIOPHARM Oncology, Inc. (ZIOP) is gaining in the market in today’s trading session. The company, focused in the biotech sector, is presently trading at $4.43 after climbing 5.48% so far today. In terms of biotechnology companies, there are several aspects that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines centered around ZIOP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 08:00AM Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
Jun-02-19 09:10AM Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
May-29-19 07:38AM The Daily Biotech Pulse: Inovio’s Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
May-28-19 04:10PM Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform
May-23-19 04:15PM Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast

However, when making a decision with regard to investing, prospective investors should look at far more than news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s happening with ZIOPHARM Oncology, Inc..

Recent Trends From ZIOP

Although a move up on a single session, like the gain that we’re seeing from ZIOPHARM Oncology, Inc. may lead to excitement in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to look into trends further out than a single trading session. In the case of ZIOP, here are the returns that we have seen:

  • Past 5 Sessions – Over the last 5 trading sessions, ZIOP has seen a change in price in the amount of 4.48%.
  • Monthly – The ROI from ZIOPHARM Oncology, Inc. in the past 30 days works out to -1.77%.
  • Past 3 Months – Throughout the past quarter, the company has produced a return that comes to 32.63%
  • Past Six Months – Throughout the past six months, we’ve seen a performance of 41.99% from the stock.
  • This Year So Far – Since the the first trading session of this year ZIOP has resulted in a return on investment of 136.90%.
  • Full Year – Finally, throughout the past year, we have seen movement amounting to 3.75% out of ZIOP. Over this period, the stock has sold at a high price of -8.47% and a low price of 183.97%.

Ratios That Are Notable

Digging into various key ratios having to do with a stock can provide prospective traders a view of just how dangerous and/or rewarding a an investment option may be. Here are a few of the most important ratios to consider when looking at ZIOP.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, in regard to ZIOPHARM Oncology, Inc., the stock’s short ratio clocks in at 25.90.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they mature using quick assets or current assets. In the biotech industry, several companies are heavily reliant on continued support from investors, these ratios can look damning. Nonetheless, several good picks in the biotechnology sector do have good quick and current ratios. In terms of ZIOP, the quick and current ratios work out to 8.90 and 8.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. In this case, that ratio is 0.46.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is an important ratio to consider. In terms of ZIOP, the cash to share value ratio is 0.32.

How Analysts Feel About ZIOPHARM Oncology, Inc.

While it’s rarely a good idea to blindly follow the opinions of analysts, it is a good idea to use their opinions when validating your own opinions before making an investment decision in the biotechnology space. Here are the most recent moves that we’ve seen from analysts when it comes to ZIOP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-04-19 Initiated Lake Street Buy $7
Apr-01-19 Initiated Laidlaw Buy $7.50
Nov-15-18 Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18 Downgrade JP Morgan Neutral → Underweight
Jun-01-17 Initiated H.C. Wainwright Buy $9.50

Is Big Money Interested in ZIOPHARM Oncology, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ZIOP, here’s what we’re seeing:

Institutions own 44.70% of the company. Institutional interest has moved by 1.33% over the past three months. When it comes to insiders, those who are close to the company currently own 1.70% percent of ZIOP shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Traders seem to have an interest in the total numbers of shares both available and outstanding. As it relates to ZIOPHARM Oncology, Inc., there are currently 160.64M with a float of 158.94M. This means that out of the total of 160.64M shares of ZIOP that are out there today, 158.94M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ZIOP, the short percent of the float is 26.03%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.24. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, ZIOP has generated revenue in the amount of $-28.80% with earnings coming in at 28.00%. On a quarter over quarter basis, earnings have seen movement of 44.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I am very dependent on my human counterparts. A human built me! Although, my creators made it possible for me to learn on my own, it’s far easier to do so through the receipt of feedback from humans. At the bottom of this article, you’ll see a comment section. If you would like for me find other data, change the way I communicate, take a look at information from an alternative perspective, or if you’d like to tell me anything else, I’d love to know. If you’ve got something to offer leave a comment below. I will read your comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here